Latest news with #iRhythmTechnologies
Yahoo
21-05-2025
- Business
- Yahoo
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time) Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time) Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Interested parties may access live and archived webcasts of the presentations on the 'Events & Presentations' section of the company's investor website at About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at Investor Contact Stephanie Zhadkevich investors@ Media Contact Kassandra Perryirhythm@
Yahoo
21-05-2025
- Business
- Yahoo
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time) Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time) Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Interested parties may access live and archived webcasts of the presentations on the 'Events & Presentations' section of the company's investor website at About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at Investor Contact Stephanie Zhadkevich investors@ Media Contact Kassandra Perryirhythm@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 20.3% year on year to $158.7 million. The company's full-year revenue guidance of $695 million at the midpoint came in 2% above analysts' estimates. Its non-GAAP loss of $0.96 per share was 2.5% below analysts' consensus estimates. Is now the time to buy IRTC? Find out in our full research report (it's free). Revenue: $158.7 million vs analyst estimates of $153.6 million (20.3% year-on-year growth, 3.3% beat) Adjusted EPS: -$0.96 vs analyst expectations of -$0.94 (2.5% miss) Adjusted EBITDA: -$2.64 million vs analyst estimates of -$5.03 million (-1.7% margin, 47.6% beat) The company lifted its revenue guidance for the full year to $695 million at the midpoint from $680 million, a 2.2% increase Operating Margin: -20.5%, up from -28.9% in the same quarter last year Free Cash Flow was -$17.31 million compared to -$61.81 million in the same quarter last year Market Capitalization: $4.5 billion iRhythm's first quarter results were shaped by accelerated adoption of its Zio AT product and increasing penetration in primary care channels. CEO Quentin Blackford pointed to strong demand from both new and existing accounts, as well as record onboarding of healthcare providers, as key contributors to the robust unit volume growth. Management highlighted the growing share of long-term continuous monitoring prescriptions originating from primary care settings, emphasizing early diagnosis benefits and improved clinical outcomes for patients previously unaware of arrhythmias. Looking ahead, the company's updated full-year guidance reflects confidence in continued momentum from both Zio AT and undiagnosed arrhythmia monitoring through innovative channel partners. CFO Daniel Wilson stated, 'Zio AT performance was a primary driver of our guidance raise, while innovative channel partners are contributing but remain an emerging opportunity.' Management acknowledged macroeconomic uncertainty but maintained that operational efficiencies, product mix, and upstream care pathway expansion are expected to drive sustainable growth for the remainder of the year. Management attributed the quarter's performance to expansion in core U.S. markets, increased adoption among primary care providers, and strong uptake of the Zio AT product. The company also referenced momentum in international markets and ongoing operational efficiency initiatives. Zio AT Momentum: The Zio AT mobile cardiac telemetry device saw significant uptake, benefiting from both new and existing account additions. Management believes features like 14-day continuous wear differentiate it versus competitors, driving retention and market share gains within the MCT segment. Primary Care Channel Expansion: Nearly one third of long-term continuous monitoring volumes now originate from primary care physicians, up from the low 20s percent a year and a half ago. Management credits its 'land-and-expand' strategy for enabling earlier detection and diagnosis of cardiac arrhythmias, particularly among patients with comorbidities who might otherwise be undiagnosed. Innovative Channel Partners: Contribution from value-based care partners focused on undiagnosed arrhythmia monitoring increased, though still represents a low single-digit percentage of total volume. Management described this as an early-stage but high-potential growth avenue for expanding the market beyond traditional cardiology. International Progress and Japan Launch: The company launched Zio in Japan, the world's second-largest ambulatory cardiac monitoring market, albeit at reimbursement rates equivalent to existing Holter monitors. iRhythm aims to generate local clinical evidence to secure higher reimbursement in the future. European markets, especially the UK, continued to deliver record volume. Regulatory and Operational Focus: Ongoing remediation and compliance activities with the FDA, including addressing warning letter observations, remain a top corporate priority. Management expects to complete remediation efforts by the end of 2025 and has allocated resources to ensure uninterrupted product supply in light of tariff and supply chain uncertainties. Management's outlook for the year centers on sustaining Zio AT momentum, expanding the primary care channel, and executing on operational efficiency, while navigating macroeconomic and reimbursement risks. Sustained Zio AT Growth: Expectations for continued above-average growth from the Zio AT product underpin revenue guidance, as management anticipates retention of recent share gains and further penetration in existing accounts. Primary Care and Innovative Partnerships: The company plans to deepen its presence in primary care and value-based care channels, aiming to address a broader population of undiagnosed arrhythmia patients and expand the total addressable market. Tariff and Supply Chain Risks: Management highlighted potential headwinds from tariffs on imported components and supply chain disruptions, but indicated mitigation strategies are underway, including building inventory and exploring supply chain adjustments. Pricing actions will be considered as a secondary lever. Allen Gong (JPMorgan): Asked about drivers behind the guidance raise and confidence for the rest of the year. Management cited sustained Zio AT momentum and a robust pipeline from innovative channel partners but emphasized caution in embedding emerging contributions into guidance. Kallum Titchmarsh (Morgan Stanley): Inquired about the stickiness of Zio AT share gains and how this frames expectations for the upcoming Zio MCT launch. CEO Quentin Blackford noted that established relationships in existing accounts and product features were key to customer retention and future cross-selling potential. Macauley Kilbane (William Blair): Sought clarification on the impact of Epic Aura integration for workflow efficiencies and volume growth. Management reported early signs of increased prescribing patterns but stated these benefits are not yet fully factored into guidance. Suraj Kalia (Oppenheimer): Requested more detail on growth across different business segments. CFO Daniel Wilson explained that Zio AT outpaced company average growth, primary care volumes now exceed one third of total, and innovative channel partners contributed a small but growing share. Sam Eiber (BTIG): Asked about strategies to offset tariff impacts, specifically whether price increases were under consideration. Management replied that supply chain adjustments are the primary mitigation strategy, with pricing actions as a secondary option. Looking ahead, the StockStory team will monitor (1) the trajectory of Zio AT adoption and retention in both existing and new accounts, (2) the pace of expansion and volume contribution from primary care and innovative channel partners, and (3) progress on international launches, particularly in Japan and Europe. Execution on FDA remediation milestones and the timeline for filing and approval of the next-generation Zio MCT device will also be closely watched. iRhythm currently trades at a forward EV-to-EBITDA ratio of 78.7×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
11-05-2025
- Business
- Yahoo
Why iRhythm Technologies (IRTC) Is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where iRhythm Technologies, Inc. (NASDAQ:IRTC) stands against other best performing healthcare stocks to buy now. On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector. Trump directed his health department to collaborate with Congress to revamp a law allowing Medicare to negotiate prescription drug prices. The announcement seeks to bring a change that the pharmaceutical company has lobbied for. Since the negotiation process is included in legislation, Trump's executive order cannot implement the change itself. However, it directs Secretary of Health and Human Services Robert F. Kennedy Jr. to join hands with Congress and change it. CNBC reported that drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years. This typically includes pills and most medications. This goes hand in hand with the 13-year wait until more complex biotech drugs are eligible for Medicare price negotiations. Trump's wide-ranging executive order also focuses on slashing healthcare costs. It comes a day after the administration instituted a national security report on the pharma industry. CNBC called the report 'a precursor to sector-specific tariffs.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. Medicare's negotiating powers have been a subject of contention, as drug makers have opined that they would suppress innovation and have rallied against the time frame for negotiation eligibility for most drugs. The law now allows the government to negotiate prices for drugs with no competition, which includes complex biotech or biologic medications after 13 years on the market, but 9 years for their administration as capsules and pills. Although they did not provide specifics, White House officials told reporters that other changes to the negotiation process would yield more savings than those attained during the first round under the Biden administration. While the Biden administration negotiated price cuts as steep as 79% for the first ten most expensive drugs to the Medicare program, the Trump administration would negotiate prices for the following 15 medications. This includes Pfizer's cancer drugs Ibrance and Xtandi, as well as Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy. We used Finviz to screen healthcare stocks and selected the best performers based on their year-to-date (YTD) performance, as of May 9, 2025. We also included the number of hedge fund holders for each stock as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is sorted in ascending order of year-to-date performance. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. YTD Performance: 52.71% Number of Hedge Fund Holders: 24 iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company that provides design, development, and commercialization of device-based technology. It provides ambulatory cardiac monitoring services, along with solutions to detect, predict, and prevent disease. On May 2, analyst William Plovanic from Canaccord Genuity revisited iRhythm Technologies, Inc. (NASDAQ:IRTC) and maintained a Buy rating on the stock with a $139.00 price target. The analyst highlighted the company's potential and strong performance, reasoning that it underwent a significant 20.3% year-over-year growth in its fiscal Q1 2025 revenue, exceeding internal and consensus estimates. The growth was attributed to the success and unexpected strength of iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Zio AT product, which is anticipated to continue its positive trajectory. The analyst further said the company raised its profitability and revenue guidance for fiscal year 2025, demonstrating confidence in sustained product demand. iRhythm Technologies, Inc. (NASDAQ:IRTC) is also progressing on regulatory fronts. It plans to submit the Zio Monitor in Q3 and complete compliance efforts by the end of 2025. It is the fourth best-performing healthcare stock to buy now on our list. Overall, IRTC ranks 4th on our list of the best performing healthcare stocks to buy now. While we acknowledge the potential for IRTC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IRTC but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
03-05-2025
- Business
- Yahoo
iRhythm Technologies First Quarter 2025 Earnings: Beats Expectations
Revenue: US$158.7m (up 20% from 1Q 2024). Net loss: US$30.7m (loss narrowed by 33% from 1Q 2024). US$0.97 loss per share (improved from US$1.47 loss in 1Q 2024). Our free stock report includes 1 warning sign investors should be aware of before investing in iRhythm Technologies. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%. Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are up 24% from a week ago. Before we wrap up, we've discovered 1 warning sign for iRhythm Technologies that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
